- Home
- AKYA vs SAVA Comparison
AKYA vs SAVA Comparison
Compare AKYA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- SAVA
- Stock Information
- Founded
- AKYA 2015
- SAVA 1998
- Country
- AKYA United States
- SAVA United States
- Employees
- AKYA N/A
- SAVA N/A
- Industry
- AKYA Medical Specialities
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- AKYA Industrials
- SAVA Health Care
- Exchange
- AKYA Nasdaq
- SAVA Nasdaq
- Market Cap
- AKYA 145.5M
- SAVA 134.2M
- IPO Year
- AKYA 2021
- SAVA N/A
- Fundamental
- Price
- AKYA $2.49
- SAVA $2.35
- Analyst Decision
- AKYA Buy
- SAVA Buy
- Analyst Count
- AKYA 7
- SAVA 3
- Target Price
- AKYA $4.40
- SAVA $111.50
- AVG Volume (30 Days)
- AKYA 392.7K
- SAVA 12.5M
- Earning Date
- AKYA 11-14-2024
- SAVA 11-07-2024
- Dividend Yield
- AKYA N/A
- SAVA N/A
- EPS Growth
- AKYA N/A
- SAVA N/A
- EPS
- AKYA N/A
- SAVA N/A
- Revenue
- AKYA $86,815,000.00
- SAVA N/A
- Revenue This Year
- AKYA N/A
- SAVA N/A
- Revenue Next Year
- AKYA $11.76
- SAVA N/A
- P/E Ratio
- AKYA N/A
- SAVA N/A
- Revenue Growth
- AKYA N/A
- SAVA N/A
- 52 Week Low
- AKYA $1.88
- SAVA $2.23
- 52 Week High
- AKYA $6.31
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- AKYA 51.92
- SAVA 22.79
- Support Level
- AKYA $2.20
- SAVA $2.78
- Resistance Level
- AKYA $2.63
- SAVA $3.28
- Average True Range (ATR)
- AKYA 0.23
- SAVA 0.23
- MACD
- AKYA 0.05
- SAVA 0.59
- Stochastic Oscillator
- AKYA 68.66
- SAVA 9.09
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.